UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~March~~April 307, 2023

Eucrates Biomedical Acquisition Corp.

(Exact name of registrant as specified in its charter)

British Virgin Islands	001-39650	N/A
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

250 West 55th Street, Suite 13D

New York, New York 10019

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 212-710-5220

Not Applicable

(Former name or former address, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class:	Trading Symbols	Name of Each Exchange on Which Registered:
Ordinary shares, no par value	EUCR	Nasdaq Capital Market
Warrants, each whole warrant exercisable for one ordinary share at an exercise price of $11.50 per share	EUCRW	Nasdaq Capital Market
Units, each consisting of one Ordinary Shares and one-third of one warrant	EUCRU	Nasdaq Capital Market

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 28.0301 ~~Creation~~Other ~~of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant~~Events.

AsOn ~~previously~~April ~~disclosed~~7, on2023, ~~February~~the ~~15,~~board ~~2023,~~of directors (the “Board”) of Eucrates Biomedical Acquisition Corp. (the “Company”) ~~issued~~approved anthe ~~unsecured~~redemption ~~promissory~~of ~~note~~all (of the ~~“Promissory~~outstanding ordinary shares ~~Note”)~~of tothe ~~Eucrates~~Company, ~~LLC~~no par value, that were included in the Company’s initial public offering (the “~~Sponsor~~Public Shares”). The Company ~~Promissory~~anticipates ~~Note provides~~ that ~~the~~it ~~Company~~will ~~may~~not ~~borrow~~be upable to consummate an initial business combination within the time period required by its Amended ~~aggregate~~and ~~maximum~~Restated ~~amount~~Memorandum and Articles of ~~$500~~Association,~~000~~ ~~from~~and as a result the ~~Sponsor,~~Company ~~$96,000~~intends ofto ~~which~~dissolve ~~was~~and ~~drawn~~liquidate. byThe redemption of the ~~Company~~Public Shares is expected to be completed on ~~February~~April 1527, 2023. OnAs ~~March~~of 31the close of business on April 26, 2023, the Company ~~drew~~will anstop trading ~~additional~~its ~~$150~~Public Shares,~~000~~ onand each Public Share held at that time will represent the ~~Promissory~~right ~~Note~~to receive the redemption amount of approximately $10.00.

~~The~~On ~~Promissory~~April ~~Note does not bear any interest. If the Company completes an initial business combination~~11, ~~the Company would repay outstanding loaned amounts under the Promissory Note. In the event that the Company is unable to complete an initial business combination~~2023, the Company ~~may~~issued ~~use~~ a ~~portion~~press ofrelease announcing the ~~working capital held outside its trust account to repay such loaned amounts but no proceeds from its trust account would be used for such repayment~~foregoing. ~~The loans~~A ~~are~~copy ~~convertible into units~~ of the ~~Company,~~press atrelease ais ~~price~~attached ofhereto ~~$10.00~~as ~~per~~Exhibit ~~unit, at the option of the Sponsor~~99.1 ~~The~~and ~~units~~is ~~would~~incorporated beherein ~~identical to~~by ~~those units that were issued to the Sponsor in a private placement concurrent with the Company’s initial public offering~~reference.

~~The~~Item ~~foregoing summary of the Promissory Note is qualified in its entirety by reference to the text of the Promissory Note, which was filed as Exhibit 10~~9.101 toFinancial ~~the~~Statements ~~Company’s Current Report on Form 8-K on February 16, 2023~~ and ~~is incorporated by reference herein~~Exhibits.

~~SIGNATURE~~(d) Exhibits:

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Exhibit		Description
99.1		Press Release, dated April 11, 2023
104		Cover Page Interactive Data File (formatted as Inline XBRL document).

~~Dated:~~SIGNATURE ~~April 3, 2023~~

~~EUCRATES~~Pursuant ~~BIOMEDICAL~~to ~~ACQUISITION~~the ~~CORP.~~requirements ~~By:~~of ~~/s/~~the ~~Gonzalo~~Securities Exchange ~~Cordova~~Act ~~Name:~~of ~~Gonzalo~~1934, ~~Cordova~~the ~~Title:~~registrant ~~Chief~~has ~~Financial~~duly ~~Officer~~caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 11, 2023

	EUCRATES BIOMEDICAL ACQUISITION CORP.

	By:	/s/ Gonzalo Cordova
		Name: Gonzalo Cordova
		Title: Chief Financial Officer

Filing Compare · Eucrates Biomedical Acquisition Corp.